119 related articles for article (PubMed ID: 7315355)
41. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival.
Levin I; Klein T; Goldstein J; Kuperman O; Kanetti J; Klein B
Cancer; 1991 Dec; 68(12):2591-4. PubMed ID: 1933807
[TBL] [Abstract][Full Text] [Related]
42. Suppression of antitumor lymphocyte mediated cytotoxicity by human chorionic gonadotropins.
Lange PH; Hakala TR; Fraley EE
J Urol; 1976 Jan; 115(1):95-8. PubMed ID: 942753
[TBL] [Abstract][Full Text] [Related]
43. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro.
Wang ZP; Zheng RL; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910
[TBL] [Abstract][Full Text] [Related]
44. Suppressive effect of prednisolone on cytotoxicity of lymphocytes from normal persons against T24 cells.
Nemoto R; Kato T
Gan; 1979 Feb; 70(1):95-100. PubMed ID: 446979
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder.
Carballido J; Alvarez-Mon M; Solovera OJ; Menéndez-Ondina L; Durántez A
J Urol; 1990 Jan; 143(1):29-33. PubMed ID: 2294256
[TBL] [Abstract][Full Text] [Related]
46. Cell-mediated cytotoxicity against human bladder cancer.
Bloom ET; Ossorio RC; Brosman SA
Int J Cancer; 1974 Sep; 14(3):326-34. PubMed ID: 4477556
[No Abstract] [Full Text] [Related]
47. Immunological characterization of cell lines establishing from malignant and normal human urothelium.
Vilien M; Wolf H; Rasmussen F
Eur J Cancer (1965); 1981 Mar; 17(3):321-7. PubMed ID: 7262169
[No Abstract] [Full Text] [Related]
48. Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24.
Catalona WJ; Oldham RK; Djeu JY; Herberman RB; Cannon GB
Surg Forum; 1975; 26():122-4. PubMed ID: 56048
[No Abstract] [Full Text] [Related]
49. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines.
Jackson AM; Hawkyard SJ; Prescott S; Ritchie AW; James K; Chisholm GD
J Urol; 1992 Jan; 147(1):207-11. PubMed ID: 1729534
[TBL] [Abstract][Full Text] [Related]
50. The use of Fab fragments of anti-human immunoglobulin as analytic tools for establishing the involvement of immunoglobulin in the spontaneous cytotoxicity to cultured tumor cells by lymphocytes from patients with bladder carcinoma and from healthy donors.
Troye M; Perlmann P; Pape GR; Spiegelberg HL; Näslund I; Gidlöf A
J Immunol; 1977 Sep; 119(3):1061-7. PubMed ID: 302271
[No Abstract] [Full Text] [Related]
51. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
52. Immunoresponse of tissue infiltrating lymphocytes in bladder tumors.
Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
J Urol; 1989 Jun; 141(6):1467-70. PubMed ID: 2657115
[TBL] [Abstract][Full Text] [Related]
53. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
54. [Cellular immune response of bladder tumor patients: effects of aging on cytotoxic activity against T24].
Kato M
Hinyokika Kiyo; 1988 Aug; 34(8):1363-9. PubMed ID: 3195404
[TBL] [Abstract][Full Text] [Related]
55. Serum induced lymphoid cell mediated cytotoxicity to human transitional cell carcinomas of the genitourinary tract.
Hakala TR; Lange PH
Science; 1974 May; 184(4138):795-7. PubMed ID: 4856602
[TBL] [Abstract][Full Text] [Related]
56. HLA-DR antigen expression and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections.
Ioachim-Velogianni E; Stavropoulos NE; Kitsiou E; Stefanaki S; Agnantis NJ
J Pathol; 1994 Nov; 174(3):183-9. PubMed ID: 7823251
[TBL] [Abstract][Full Text] [Related]
57. Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells.
Wang ZP; Duan GL; Chen YR; Qin DS; Liu GD; Niu HG
Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):276-8. PubMed ID: 10452107
[TBL] [Abstract][Full Text] [Related]
58. The value of CEA assay in tissue, serum and urine in patients with transitional cell carcinoma of the bladder.
Alampi G; Ronchi E; Galassi A; Soli M; Botteghi B; Bercovich E
Arch Anat Cytol Pathol; 1985; 33(4):193-6. PubMed ID: 3904640
[No Abstract] [Full Text] [Related]
59. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis.
Soslow RA; Rouse RV; Hendrickson MR; Silva EG; Longacre TA
Int J Gynecol Pathol; 1996 Jul; 15(3):257-65. PubMed ID: 8811388
[TBL] [Abstract][Full Text] [Related]
60. Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder.
Bubeník J
Int Urol Nephrol; 1975; 7(4):297-302. PubMed ID: 1107249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
